Elite Pharmaceuticals Inc (ELTP)

[imanjen13]

The fiscal year end report for the quarter ending March 31, 2023 will be filed at the end of June. That report is likely to again show record revenues and a final quarter near or in excess of 10 Million reflecting the almost final sales numbers from Lannett. We will also hear from NH regarding the progress Kirkov has made in developing a distribution network.

The first quarter, ending on June 30, will be published in Mid August, at which time NH foresees a "dip" as Elite is ramping up manufacture and inventory as it distributes 3 of its own products which will be somewhat offset by Lannett's sales of inventory Elite delivered up to the end of March. In that quarter, Elite should also see revenue from the manufacture and packaging of the Pyos product of Vigabatrin that they will launch mid year.

With such low average volume, it is not difficult to affect the stock price if someone with any decent position wants to "throw in the towel" however the opposite can occur when someone believes and wants to take a sizable position.

My guess is that today's buyer for the shares offered due to NH's dip forecast is getting a good deal.